

**adalimumab 40mg solution for injection (Humira®)**  
**(No: 533/09)**

**Abbott Laboratories**

**Product Update**

09 January 2009

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**adalimumab (Humira)** is accepted for restricted use in NHS Scotland, in combination with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis in adolescents aged 13-17 years who have an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

It should be restricted to use within specialist rheumatology services (including those working within the network for paediatric rheumatology). Adalimumab is one of three TNF-antagonists listed in the British National Formulary for Children as drugs that suppress the rheumatic disease process, and one of two of those drugs licensed for active polyarticular juvenile idiopathic arthritis.

The Scottish Medicines Consortium has previously accepted this product for restricted use for this indication in adults.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 28 November 2008.*

**Chairman**  
**Scottish Medicines Consortium**